SCHEMBL3159077

SCHEMBL3159077

CC(c1cccc(P)c1C(C)P(c1ccccc1)c1ccccc1)P(c1ccccc1)c1ccccc1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SOAT2 O75908 1/20 0.30
SOAT1 P35610 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454194 0.85 CYP3A4 (0.32)
SCHEMBL2880133 0.79 CYP3A4 (0.30)
SCHEMBL8467150 0.79 CYP3A4 (0.39) SOAT2SOAT1
SCHEMBL3169255 0.76
SCHEMBL7059781 0.71 ALDH1A1 (0.47)
SCHEMBL27504866 0.71 ADRA2A (0.39)
SCHEMBL27908650 0.71 GABRA1 (0.54)
SCHEMBL27991666 0.70 CD44 (0.36)
SCHEMBL3963448 0.69 CYP3A4 (0.41)
SCHEMBL5266052 0.67 TSHR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624276-B2 Compositions and methods for the dissolution of iron sulfide SOLUGEN, INC. (US) 2026-05-12 US claimed
EP-4090654-B1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LTD (IN) 2025-07-09 EP claimed
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds LUPIN LIMITED (IN) 2025-07-01 US claimed
WO-2025042851-A1 BIO-BASED DETERGENT BUILDER SOLUGEN, INC. (US) 2025-02-27 WO claimed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US claimed
EP-4090654-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS Lupin Limited (IN) 2022-11-23 EP claimed
WO-2022226401-A1 COMPOSITIONS AND METHODS FOR THE DISSOLUTION OF IRON SULFIDE SOLUGEN, INC. (US) 2022-10-27 WO claimed
WO-2021144814-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2021-07-22 WO claimed
US-9475889-B2 Photoinitiator and photocurable compositions and uses EASTMAN KODAK COMPANY (US) 2016-10-25 US claimed
US-20150126637-A1 PHOTOINITIATOR AND PHOTOCURABLE COMPOSITIONS AND USES BANK OF AMERICA, N.A., AS AGENT 2015-05-07 US claimed
EP-2710044-B1 PHOTOINITIATOR AND PHOTOCURABLE COMPOSITIONS AND USES EASTMAN KODAK CO (US) 2015-04-01 EP claimed
EP-2710044-A1 PHOTOINITIATOR AND PHOTOCURABLE COMPOSITIONS AND USES Eastman Kodak Company (US) 2014-03-26 EP claimed
US-8664287-B2 Photocuring methods and articles prepared therefrom Eastman Kodah Company (US) 2014-03-04 US claimed
US-20120295035-A1 PHOTOCURING METHODS AND ARTICLES PREPARED THEREFROM BANK OF AMERICA, N.A., AS AGENT 2012-11-22 US claimed
US-20120295999-A1 PHOTOINITIATOR AND PHOTOCURABLE COMPOSITIONS AND USES NPEC INC. 2012-11-22 US claimed
WO-2012158660-A1 PHOTOINITIATOR AND PHOTOCURABLE COMPOSITIONS AND USES EASTMAN KODAK COMPANY (US) 2012-11-22 WO claimed
EP-0531256-B1 Method for preparing glycosides CIBA GEIGY AG (CH) 1997-04-23 EP claimed
US-5342929-A Direct glycosylation leads to the desired glycosides in high yield and relatively short reaction times using metal complex salts; large amounts of the alpha- or beta-form are often obtained CIBA-GEIGY CORPORATION (US) 1994-08-30 US claimed
US-20260136848-A1 DEPOSITION OF METAL-CONTAINING FILMS LAM RES CORP (US) 2026-05-14 US disclosed
US-4594463-A HYDROFORMYULATION UNION CARBIDE CORPORATION (US) 1986-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS CASR, CALCR, RYR1 SOAT2 3122/4885SOAT1 2804/4885
US-20260136848-A1 DEPOSITION OF METAL-CONTAINING FILMS TPO, TTI2, ABL1 SOAT2 856/4885SOAT1 1026/4885
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds CASR, CALCR, RYR1 SOAT2 3122/4885SOAT1 2804/4885
US-12624276-B2 Compositions and methods for the dissolution of iron sulfide MGAT2, SLC7A11, CA1 SOAT2 1240/4885SOAT1 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.